UNSPSC 85811911: Introduction of oxazolidinones into eye, via natural or artificial opening

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of oxazolidinones into eye, via natural or artificial opening. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0C728

UNSPSC 85811911 Introduction of oxazolidinones into eye, via natural or artificial opening is a Commodity code with minimal recent state and local procurement activity directly aligned to its medical-pharmaceutical scope. The recent opportunities tagged to this code encompass telehealth urgent care, occupational health services, cancer screening, medical director oversight, nursing home placement, employee wellness platforms, opioid use disorder treatment and recovery services, and behavioral health programs—none of which concern ocular medication administration by the code's definition. The issuing bodies span state health authorities and departments, county governments, cities, school districts, and special-purpose districts across California, Georgia, Nevada, Colorado, Texas, Florida, Oregon, Kansas, Missouri, and other jurisdictions, reflecting broad geographic procurement activity in state and local healthcare contracting. However, the mismatch between the UNSPSC code's literal scope and the work actually being solicited signals that this code shows little relevant recent activity in state and local procurement markets.

The source provides no recent opportunities where state or local governments are actually procuring oxazolidinone eye medications or related pharmaceutical services under this code. Instead, the opportunities reflect healthcare administration, care coordination, provider staffing, screening and diagnostic services, recovery programming, and wellness infrastructure—service families far removed from the administration of a specific drug class to the eye. When state and local procurement data tags opportunities incorrectly or when a code's abstract definition diverges widely from market activity, the code itself remains a poor signal for business development professionals seeking to understand current demand. This code warrants continued monitoring if pharmaceutical procurement activity emerges, but present evidence does not support pursuit of opportunities under it.